GlassScriptPhysician profile
Ryan Scott Rhodes
NPI 1013531045
$4,889.69
in general payments reported to CMS, 2019-2025
18 companies · $1,177 in 2025
The $1,177 reported for 2025 was more than what 81% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $11.43 · 2021: $234 · 2022: $522 · 2023: $1,097 · 2024: $1,849 · 2025: $1,177.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,122.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,122.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,949.68 | 2023-2025 | Clareon, Hydrus Microstent, Argos |
| Bausch & Lomb Americas INC. | $568.71 | 2022-2025 | Envista Mx60 Iol, Miebo, Stellaris |
| Abbvie INC. | $455.74 | 2022-2025 | |
| Sight Sciences, INC. | $444.05 | 2024-2025 | Omni Surgical System, Sion Surgical Instrument |
| Johnson & Johnson Surgical Vision, INC. | $211.06 | 2023-2024 | Tecnis Iol |
| Glaukos Corporation | $173.44 | 2023-2025 | Idosetr, Istent Infinite |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $134.13 | 2021 | |
| Harrow Eye, LLC | $121.80 | 2024 | Verkazia, Flarex, Iheezo |
| Axogen | $121.29 | 2023 | Avance Nerve Graft |
| Regeneron Healthcare Solutions, INC. | $114.15 | 2024 | Eylea Hd |
| Horizon Therapeutics Plc | $113.27 | 2022 | |
| Carl Zeiss Meditec USA, INC. | $111.68 | 2023-2024 | Forum, Iolmaster 700 |
| Allergan, INC. | $99.99 | 2021 | |
| Astellas Pharma US INC | $98.68 | 2024 | Izervay |
| New World Medical,INC. | $96.22 | 2024 | Streamline, Ahmed Glaucoma Valve, Kahook Dual Blade |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Oyster Point Pharma, INC. | $48.20 | 2025 | Tyrvaya, Ryzumvi |
| Apellis Pharmaceuticals, INC. | $16.17 | 2025 | Syfovre |
| Mission Pharmacal Company | $11.43 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Rhodes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.